Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing FacilityRead Announcement
By integrating drug substance, drug product, and clinical testing activities, Translational Pharmaceutics® accelerates molecules through development. This saves time and money in reaching key milestones as quickly and efficiently as possible, ensuring better decision making and more streamlined outsourcing.
Our expertise in understanding dependencies between drug substance properties, formulation design, and clinical outcomes enables us to enhance development efficiency.
By having both drug substance and drug product manufacturing activities under one organization, we can now deliver integrated chemistry, manufacturing, and controls (CMC) development activities for both pre-clinical and clinical studies in parallel, simplifying the supply chain and shortening the time from candidate selection to clinic by a further 2–4 months.
Translational Pharmaceutics® has now been used by pharmaceutical and biotech companies on over 500 drug programs. The financial benefits and time savings were quantified in a publication by the Tufts Center for the Study of Drug Development.
The seamless coordination between drug substance and drug product manufacturing results in a more efficient and accelerated development plan. Integrating all activities under a single organization, removing silos, encourages close relationships between multidisciplinary experts and creates a more agile approach to pharmaceutical development. Learn how a fully integrated program can speed up the transition from candidate selection to POC and shorten the pathway to clinical development.
"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."
In this latest blog written by Quotient Sciences' Chief Scientific Officer, Dr Peter Scholes, he talks about the complexities and importance in selecting the right outsourcing partner for your drug development program. He also discusses how the climate of the pharmaceutical industry today can be challenging for drug developers to manage multiple vendors, projects can be slow to start, disconnects can lead to delayed timelines, and it can be extremely costly, which points to a need for a simplified outsourcing model.